Aims: To evaluate the use of computed tomography image-guided percutaneous cryoablation for recurrent retroperitoneal soft tissue sarcomas (RPSs).Results: Adverse events were limited to grades 1 and 2,included fever (n=19), local pain (n=11), emesis (n=10),frostbite (n=6), and nerve injury (n=1).Fever was more frequent in the large tumor group (15.8%) than in small tumor group (1.9%) (P=0.008).Median PFS and OS were 37.0±7.7 months (range, 4-39 months) and 43.0±5.9months (range, 6-54 months), respectively.PFS and OS were signifcantly longer in the small tumor group than in the large tumor group (P=0.011 and P=0.015,respectively), but the response rate (82.7% vs.72.8%,P=0.240) did not differ signifcantly.On univariate analysis,tumor size, tumor invasion grade, and distant metastasis were signifcant prognostic factors for PFS and OS.On multivariate analysis, a tumor size ≥ 10cm was an independent negative prognostic factor for PFS and OS after cryoablation (HR: 3.98, 95% CI: 1.27-12.50, P=0.018and HR: 4.33, 95% CI: 1.41-13.26, P=0.010, respectively).Materials and Methods: Data from 72 patients with recurrent RPSs who underwent percutaneous cryoablation were reviewed retrospectively.The prognostic factors for progression-free survival (PFS),overall survival (OS), and effcacy based on mRECIST criteria were analysis.Adverse events were compared according to tumor size (<10 and ≥ 10cm).Conclusion: Minimally invasive percutaneous cryoablation was safe and effcacious for recurrent RPSs.